Cargando…

Brigatinib Dose Rationale in Anaplastic Lymphoma Kinase–Positive Non‐Small Cell Lung Cancer: Exposure–Response Analyses of Pivotal ALTA Study

Brigatinib is a kinase inhibitor indicated for patients with advanced anaplastic lymphoma kinase–positive non‐small cell lung cancer who progressed on or are intolerant to crizotinib. Approval was based on results from a randomized, dose‐ranging phase II study (ALK in Lung Cancer Trial of AP26113 (A...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gupta, Neeraj, Wang, Xiaohui, Offman, Elliot, Rich, Benjamin, Kerstein, David, Hanley, Michael, Diderichsen, Paul M., Zhang, Pingkuan, Venkatakrishnan, Karthik
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7762810/ https://www.ncbi.nlm.nih.gov/pubmed/33185028 http://dx.doi.org/10.1002/psp4.12569

Ejemplares similares

Clinical Pharmacology of Brigatinib: A Next-Generation Anaplastic Lymphoma Kinase Inhibitor
por: Gupta, Neeraj, et al.
Publicado: (2023)

Population Pharmacokinetics of Brigatinib in Healthy Volunteers and Patients With Cancer
por: Gupta, Neeraj, et al.
Publicado: (2020)

The Effect of a High‐Fat Meal on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers
por: Tugnait, Meera, et al.
Publicado: (2018)

Population pharmacokinetic and exposure‐response analyses from ALTA‐1L: Model‐based analyses supporting the brigatinib dose in ALK‐positive NSCLC
por: Gupta, Neeraj, et al.
Publicado: (2022)

Corrigendum to: Brigatinib dose rationale in anaplastic lymphoma kinase–positive non‐small cell lung cancer: Exposure–response analyses of pivotal ALTA study
Publicado: (2021)

Effect of severe renal impairment on the pharmacokinetics of brigatinib
por: Gupta, Neeraj, et al.
Publicado: (2021)

Brigatinib pharmacokinetics in patients with chronic hepatic impairment
por: Hanley, Michael J., et al.
Publicado: (2023)

Effects of Strong CYP2C8 or CYP3A Inhibition and CYP3A Induction on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers
por: Tugnait, Meera, et al.
Publicado: (2019)

Pharmacometric analyses and clinical evidence for brigatinib dosing in anaplastic lymphoma kinase‐positive non‐small cell lung cancer
por: Gupta, Neeraj, et al.
Publicado: (2022)

Population pharmacokinetic/pharmacodynamic joint modeling of ixazomib efficacy and safety using data from the pivotal phase III TOURMALINE‐MM1 study in multiple myeloma patients
por: Srimani, Jaydeep K., et al.
Publicado: (2022)

Mobocertinib Dose Rationale in Patients with Metastatic NSCLC with EGFR Exon 20 Insertions: Exposure–Response Analyses of a Pivotal Phase I/II Study
por: Gupta, Neeraj, et al.
Publicado: (2022)

Brigatinib in Japanese patients with ALK‐positive non‐small‐cell lung cancer: Final results of the phase 2 J‐ALTA trial
por: Yoshida, Tatsuya, et al.
Publicado: (2023)

Brigatinib Versus Crizotinib in Advanced ALK Inhibitor–Naive ALK-Positive Non–Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial
por: Camidge, D. Ross, et al.
Publicado: (2020)

Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study
por: Sugawara, Shunichi, et al.
Publicado: (2022)

Brigatinib, an anaplastic lymphoma kinase inhibitor, abrogates activity and growth in ALK-positive neuroblastoma cells, Drosophila and mice
por: Siaw, Joachim T., et al.
Publicado: (2016)

Correction to: Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study
por: Sugawara, Shunichi, et al.
Publicado: (2022)

Correction to: Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study
por: Sugawara, Shunichi, et al.
Publicado: (2023)

Cost-effectiveness of ensartinib, crizotinib, ceritinib, alectinib, brigatinib and lorlatinib in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer in China
por: Luo, Xia, et al.
Publicado: (2022)

Current Insights on the Treatment of Anaplastic Lymphoma Kinase-Positive Metastatic Non-Small Cell Lung Cancer: Focus on Brigatinib
por: Rijavec, Erika, et al.
Publicado: (2022)

P1166: BRIGATINIB IN PATIENTS WITH ALK-POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA WHO HAVE FAILED BRENTUXIMAB VEDOTIN
por: Veleanu, Layla, et al.
Publicado: (2023)

Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) Trials
por: Gettinger, Scott N., et al.
Publicado: (2022)

Population Pharmacokinetics of Ponatinib in Healthy Adult Volunteers and Patients With Hematologic Malignancies and Model‐Informed Dose Selection for Pediatric Development
por: Hanley, Michael J., et al.
Publicado: (2021)

Synthesis and Preclinical Evaluation of [Methylpiperazine-(11)C]brigatinib as a PET Tracer Targeting Both Mutated Epidermal Growth Factor Receptor and Anaplastic Lymphoma Kinase
por: Högnäsbacka, Antonia A., et al.
Publicado: (2023)

Population Pharmacokinetic Analysis of Ixazomib, an Oral Proteasome Inhibitor, Including Data from the Phase III TOURMALINE-MM1 Study to Inform Labelling
por: Gupta, Neeraj, et al.
Publicado: (2017)

Real-World Efficacy and Tolerability of Brigatinib in Patients with Non-Small Cell Lung Cancer with Prior ALK-TKIs in the United States
por: Jahanzeb, Mohammad, et al.
Publicado: (2022)

Comparison of Efficacy and Safety of Brigatinib in First-Line Treatments for Patients with Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Systematic Review and Indirect Treatment Comparison
por: Yu, Yongfeng, et al.
Publicado: (2022)

Brigatinib for non-small cell lung cancer
Publicado: (2020)

Investigation into the Formation of Impurities during the Optimization of Brigatinib
por: Guo, Aofeng, et al.
Publicado: (2020)

Brigatinib versus other second-generation ALK inhibitors as initial treatment of anaplastic lymphoma kinase positive non-small cell lung cancer with deep phenotyping: study protocol of the ABP trial
por: Christopoulos, Petros, et al.
Publicado: (2021)

Refractory Anaplastic Large Cell Lymphoma Rescued by the Combination of the Second-Generation ALK Inhibitor Brigatinib, High-dose Chemotherapy and Allogeneic Stem Cell Transplantation: A Case Report and Review of the Literature
por: Caddeo, Giulia, et al.
Publicado: (2023)

Physiologically‐Based Pharmacokinetic Models as Enablers of Precision Dosing in Drug Development: Pivotal Role of the Human Mass Balance Study
por: Rowland Yeo, Karen, et al.
Publicado: (2020)

Exposure–response analyses for the MET inhibitor tepotinib including patients in the pivotal VISION trial: support for dosage recommendations
por: Xiong, Wenyuan, et al.
Publicado: (2022)

The Effect of a High‐Fat Meal on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor, in Patients With Advanced Solid Tumors or Lymphoma
por: Gupta, Neeraj, et al.
Publicado: (2016)

Simultaneous Quantification of Brigatinib and Brigatinib-Analog in Rat Plasma and Brain Homogenate by LC-MS/MS: Application to Comparative Pharmacokinetic and Brain Distribution Studies
por: Li, Bo, et al.
Publicado: (2019)

Dose and Schedule Selection of the Oral Proteasome Inhibitor Ixazomib in Relapsed/Refractory Multiple Myeloma: Clinical and Model-Based Analyses
por: Gupta, Neeraj, et al.
Publicado: (2017)

Primary gastric anaplastic lymphoma kinase-negative anaplastic large-cell lymphoma
por: Tian, Chen, et al.
Publicado: (2016)

Model‐Informed Drug Development for Ixazomib, an Oral Proteasome Inhibitor
por: Gupta, Neeraj, et al.
Publicado: (2018)

Randomized, open-label phase II study of brigatinib and carboplatin plus pemetrexed and brigatinib alone for chemotherapy-naive patients with ALK-rearranged non-squamous non-small cell lung cancer: treatment rationale and protocol design of the B-DASH study (WJOG 14720 L)
por: Wakuda, Kazushige, et al.
Publicado: (2023)

Leukemic manifestation of anaplastic lymphoma kinase-negative-type anaplastic large-cell lymphoma
por: Kim, Jae Wook, et al.
Publicado: (2012)

Patient-reported outcomes of brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma
por: Chen, Robert, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_1k067cp4n93m1rt7t7peaagdbg